Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients with KRAS G12D Mutant Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients with KRAS G12D Mutant Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GFH 375 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic ductal carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GenFleet Therapeutics

    • Most Recent Events

    • 23 Jan 2025 According to Verastem Oncology media release, Enrollment in the Phase 1 dose-escalation cohort is ongoing. Company to file an investigational new drug (IND) application in the U.S. for VS-7375 in Q1 2025. Company to share preclinical and clinical data from the Phase 1 study of VS-7375 in China in H1 2025.
    • 14 Jan 2025 Results presented in a Verastem Oncology media release.
    • 14 Jan 2025 According to Verastem Oncology media release, the company expect to share updated preclinical and clinical data at upcoming medical meetings in mid-2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top